Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Post by barmac6on Nov 12, 2010 8:20am
365 Views
Post# 17697251

Globe says GPS Hemisphere must locate expenses to

Globe says GPS Hemisphere must locate expenses to

Globe says GPS Hemisphere must locate expenses to cut
Ticker Symbol: C:HEM

Globe says GPS Hemisphere must locate expenses to cut

Hemisphere GPS Inc (C:HEM)
Shares Issued 55,561,676
Last Close 11/11/2010 $1.01
Friday November 12 2010 - In the News

The Globe and Mail reports in its Friday, Nov. 12, edition that Contra The Heard Investment Letter president Benj Gallander is keen on Hemisphere GPS. Clea Simos writes in The Globe's BNN Market Call column that Hemisphere GPS stock edged up a penny to finish on the TSX Venture Exchange Thursday at $1.01. Mr. Gallander says: "Hemisphere GPS has just recorded its best third quarter revenues in history. Unfortunately the company continues to lose money, due to high expenses. It is necessary for this outfit to take scissors to expenses to return to previous form. Also, a goodwill writedown would not be a surprise." Mr. Gallander targets the shares at $3 to $4.50. Mr. Gallander targets Cangene shares at $10 to $12. In his general outlook Mr. Gallander says: "Given my uncertainty where markets are going, I am quite content to be well invested, while having cash on the sidelines for cherry-picking opportunities. Certainly the amount of liquidity injected into the system bodes well for markets, but counterbalancing this is the heavy levels of debt throughout the system, from consumers to government. This will constrain the ability to invest in North American markets."

2010 Canjex Publishing Ltd.

Bullboard Posts